^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD3 agonist

    Related drugs:
    14h
    Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=18, Recruiting, University of Washington | Not yet recruiting --> Recruiting
    Enrollment open
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • Epkinly (epcoritamab-bysp) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)
    20h
    A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia (clinicaltrials.gov)
    P1/2, N=158, Recruiting, Keymed Biosciences Co.Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    21h
    A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion (clinicaltrials.gov)
    P1/2, N=76, Recruiting, AbbVie | Trial completion date: Feb 2028 --> Sep 2031 | Trial primary completion date: Oct 2026 --> Sep 2031
    Trial completion date • Trial primary completion date • Adverse events
    |
    etentamig intravenous (ABBV-383 IV)
    1d
    Phase I/II Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=30, Not yet recruiting, M.D. Anderson Cancer Center
    New P1/2 trial
    |
    Epkinly (epcoritamab-bysp) • Monjuvi (tafasitamab-cxix)
    1d
    DAREON-8: DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=46, Active, not recruiting, Boehringer Ingelheim | Trial primary completion date: Dec 2025 --> Sep 2026
    Trial primary completion date
    |
    cisplatin • Tecentriq (atezolizumab) • carboplatin • Imfinzi (durvalumab) • etoposide IV • obrixtamig (BI 764532)
    2d
    A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, M.D. Anderson Cancer Center
    New P1 trial
    |
    clonoSEQ
    |
    Revuforj (revumenib)
    2d
    Tarlatamab for small-cell lung cancer. (PubMed, Expert Opin Biol Ther)
    Most data come from SCLC; in the other two diseases, tarlatamab is in early clinical development. Tarlatamab is an effective therapy mainly in relapsed/progressed SCLC, and its assessment in limited SCLC alone or combined with other therapies is supported by the existing data.
    Review • Journal
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    Imdelltra (tarlatamab-dlle)
    3d
    Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma (clinicaltrials.gov)
    P2, N=34, Active, not recruiting, Washington University School of Medicine | Trial completion date: May 2031 --> Apr 2029 | Trial primary completion date: May 2026 --> Sep 2025
    Trial completion date • Trial primary completion date
    |
    Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)
    3d
    Organ-specific delivery of an mRNA-encoded bispecific T cell engager targeting glypican-3 in hepatocellular carcinoma. (PubMed, Nat Commun)
    No severe adverse effects or gross pathology were observed. Our results thus support the advancement of MTS105 into clinical trials, with a first-in-human study currently underway.
    Journal
    |
    CD8 (cluster of differentiation 8) • GPC3 (Glypican 3)
    3d
    Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: Oct 2025 --> Jan 2026
    Trial initiation date
    |
    carfilzomib • pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Tecvayli (teclistamab-cqyv) • Hemady (dexamethasone tablets) • dexamethasone injection
    3d
    Blinatumomab combined with low-dose chemotherapy and tyrosine kinase inhibitors as first-line induction for newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: improved efficacy and reduced toxicity. (PubMed, Front Med (Lausanne))
    Blinatumomab combined with low-dose chemotherapy and TKIs demonstrated a trend toward improved MRD negativity, lower relapse rates, and reduced hematologic toxicity compared to conventional chemotherapy. These findings support further investigation in larger trials to confirm clinical benefit.
    Journal
    |
    ABL1 (ABL proto-oncogene 1)
    |
    Blincyto (blinatumomab)
    5d
    A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6 (clinicaltrials.gov)
    P1, N=97, Recruiting, Boehringer Ingelheim | N=70 --> 97
    Enrollment change
    |
    NCR3LG1 (Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1)
    |
    ezabenlimab (BI 754091) • BI 765049